UK: UK introduces changes to patent fees

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

UK: UK introduces changes to patent fees

The UK Intellectual Property Office (UKIPO) has recently announced changes to UK patent fees. These changes follow a consultation period in 2017 and introduce some new fees as well as increasing existing fees. The changes will enter into force for UK patent applicants on April 6 2018.

The changes, related to filing, search, examination and grant affect both direct UK patent applications and UK national phase patent applications based on a corresponding international (Patent Cooperation Treaty) application. The changes to renewal fees will affect all granted UK patent applications, including those resulting from granted European patent applications.

Among these changes, the filing and search fees will both increase, alongside a new surcharge for the payment of the application fee after filing. Perhaps more significant is the introduction of a fee for excess claims. Under the previous fee structure, there was no financial penalty for filing a UK patent application with a large number of claims. However, under the changed fee structure, an excess claims fee of £20 for each claim over 25 claims will be payable alongside the search fee.

The changes also include a £20 increase to the examination fee and the introduction of a fee of £10 for each page of description over 35. Where an excess page fee is payable, this will be due alongside the examination fee. While the UK currently has no grant or issue fee for patents, after these fee changes, if the number of excess claims or excess pages increases during prosecution, a fee will be payable at grant composed of the additional excess claims fees and excess pages fees due.

Finally, as part of the changes, renewal fees for year 12 onwards will be increased by £10. Overall, the fee changes will more closely align the UKIPO's fee schedule and practice with that of the European Patent Office.

Despite these upcoming changes, fees at the UKIPO remain highly competitive relative to those of other similar sized economies. Therefore, the UK remains an attractive jurisdiction in which to file patent applications, especially for small and medium-sized businesses, and is a crucial territory within an IP strategy.

Chapman

Helga Chapman

Chapman IP

Kings Park House, 22 Kings Park Road

Southampton SO15 2AT

United Kingdom

Tel: +44 (0) 23 8000 2022 

info@chapmanip.com  

www.chapmanip.com

more from across site and SHARED ros bottom lb

More from across our site

Junior lawyers aren’t unwilling to work hard, as some seniors believe; rather, they are rejecting traditional career advancement models that have limited payoff
Rebekah Gay discusses overcoming self-doubt, supporting the next generation of women lawyers, and how changing client demands are reshaping IP practice
New filing data suggests Germany's grip on UPC litigation remains strong, while Bardehle Pagenberg, Arnold Ruess, Hogan Lovells and Carpmaels notch up notable cases
In 27 years, KASS has expanded to seven countries in southeast Asia and is now eyeing further growth opportunities. Its CEO shares her perspective
Mine Güner discusses bridging law and business, taking the initiative, and why Taylor Swift helped put copyright on the map
Cindy Goh discusses why she launched Cheang & Ariff's IP department, the improving litigation environment in Malaysia and what to consider when using AI
Increased focus on adding patent litigation depth to the firm’s Dallas office was behind the boutique’s most recent hires
IPH's Canadian acquisitions are paying off on paper, but a couple of strong years may not be enough to show that the group's strategy has truly won over the market
Examiner statistics could help patent prosecution practitioners tailor strategies, turning an area of high variability into a potential competitive advantage
The England and Wales High Court’s ruling in Accord v Novartis may not rewrite the law on plausibility, but it does signal a pragmatic approach that could provide greater certainty for life sciences innovators
Gift this article